Abstract:Abnormal lipid metabolism in Alzheimer's disease (AD) was first documented by Alois Alzheimer in his early observations of patients with a then unrecognized brain disease, which he noted was characterized by a significant presence of "adipose inclusions" or "lipoid granules". Despite this early recognition, until recently the significance of abnormal lipid metabolism in AD has been largely overlooked by the scientific community for decades, highlighting a critical gap in our understanding of this complex disease. In the past decade, numerous loci and genes with genome-wide significant evidence of affecting AD risk have been reported. Notably, a significant portion of these AD risk genes are either preferentially or exclusively expressed by microglia in the brain and/or code for enzymes that directly or indirectly regulate lipid metabolism. This suggests a major, yet uncharacterized, role of microglia in modulating brain lipid metabolism under AD pathological conditions. In our study, we dissected microglia-dependent and independent regulation of lipid metabolism in an AD-like mouse model of amyloidosis, 5xFAD, taking advantage of pharmacological and genetic interventions to eliminate microglia. Using multidimensional mass spectrometry-based shotgun lipidomics (MDMS-SL), we identified overt changes in a number of AD-associated lipids (ADALs) in postmortem patient brains and mouse models of amyloidosis. This included bis(monoacylglycerol)phosphate (BMP), a lipid class enriched in endosomal/lysosomal compartments, and the two most abundant classes of lysophospholipids: lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE), which are commonly associated with inflammation. Our findings revealed that microglial depletion prevented the accumulation of arachidonic acid-containing BMP species, which are associated with lysosomal activation induced by amyloidosis via a mechanism that involves progranulin, coded by AD risk gene GRN, as shown by targeted transcriptomics, immunoblotting, and immunofluorescence. Surprisingly, AD-associated LPC and LPE accumulation was not driven by microglia. Instead, LPC accumulation correlated with astrocytic activation, while LPE accumulation seems to be associated with oxidative stress. In summary, we uncovered novel microglia-dependent and independent mechanisms that drive lipid dysregulation in AD. These findings may be mechanistically linked with the early glial lipoid deposits described by Dr. Alzheimer.

Brain region‐specific amyloid plaque‐associated myelin lipid loss, APOE deposition and disruption of the myelin sheath in familial Alzheimer’s disease mice

Mass spectrometry imaging highlights dynamic patterns of lipid co‐expression with Aβ plaques in mouse and human brains

Investigating Regional Specificity of Alzheimer’s Disease Pathology in the 5xFAD Mouse Model

Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease

Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer’s Disease Brain

Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men

Microglia-Dependent and Independent Modulation of Brain Lipid Metabolism in Alzheimer's Disease Revealed by Pharmacological and Genetic Microglial Depletion

Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a Novel Therapeutic Target

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry

Amyloidosis is associated with thicker myelin and increased oligodendrogenesis in the adult mouse brain

Exploring the Abeta Plaque Microenvironment in Alzheimer's Disease Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer

PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease

Delineating amyloid peptide signatures among heterogenous plaque population in Alzheimer’s Disease

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Brain region-specific myelinogenesis is not directly linked to amyloid-β in APP/PS1 transgenic mice

Amyloid beta Induces Lipid Droplet-Mediated Microglial Dysfunction in Alzheimer's Disease

Multimodal mass spectrometry imaging for plaque- and region-specific neurolipidomics in an Alzheimer’s disease mouse model

Myelin Basic Protein Associates with AβPP, Aβ1-42, and Amyloid Plaques in Cortex of Alzheimer's Disease Brain.

Not all plaques are created equal: Uncovering a unique molecular signature in Alzheimer's disease

Chemical imaging signatures delineate heterogeneous amyloid plaque populations across the Alzheimers disease spectrum

Neuronal loss and microgliosis are restricted to the core of Aβ deposits in mouse models of Alzheimer's disease